Drug Profile
AZD 4573
Alternative Names: AZD-4573Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator AstraZeneca Pharmaceuticals
- Class Amides; Antineoplastics; Cyclohexanes; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 25 Mar 2024 Discontinued - Phase-II for Haematological malignancies (Combination therapy, Second-line therapy or greater) in France, Italy, South Korea, Singapore, Sweden, Taiwan, United Kingdom, USA, Australia (IV)
- 16 Feb 2024 AstraZeneca completes a phase II trial for Haematological malignancies (Monotherapy, Combination therapy, Second-line or greater therapy) in Australia, France, Italy, South Korea, Singapore, Sweden, Taiwan, United Kingdom, USA (NCT05140382)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Burkitt Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)